Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price

CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully approved by the US FDA at a lower recommended dose.

Pfizer Inc.'santibody-drug conjugateMylotarg is set to reenter the US market at the list price of $24,600 for one cycle of treatment, which is all many patients will need, the company said.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip